论文信息 - Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study - 字舞流文

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

C. Hofmeister | A. Oriol | A. Yee | J. San-Miguel | J. de la Rubia | M. Hansson | M. Mateos | K. Carlson | Shaoyi Li | B. Ferstl | I. Boss | S. Wong | C. Encinas | C. Cerchione | J. Lund | Noffar Bar | A. Bermúdez | C. Godwin | L. Paris | L. Costa | P. Ribas | P. Rodríguez-Otero | A. Gaudy | M. R. Burgess | A. Santoro | Kevin Hsu